Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 21;15(12):e252391.
doi: 10.1136/bcr-2022-252391.

Rare case of coexisting ovarian Brenner tumour and ovarian stromal hyperplasia presenting with persistent endometrial hyperplasia following treatment with levonorgestrel-intrauterine system

Zhun Wei Mok  1 , Janice Pui See Chin  2
Affiliations
Case Reports

Rare case of coexisting ovarian Brenner tumour and ovarian stromal hyperplasia presenting with persistent endometrial hyperplasia following treatment with levonorgestrel-intrauterine system

Zhun Wei Mok et al. BMJ Case Rep. .

Abstract

Endometrial hyperplasia (EH) is a precursor of endometrial cancer. It arises in an environment of unopposed oestrogen. Treatment is based on a combination of weight management, diet and exercise, and the use of progestogens either via a levonogestrel-intrauterine system (LNG-IUS) or orally. The LNG-IUS is the first-line recommendation for EH without atypia. Recurrences are rare, and any recurrences despite prolonged treatment and control of risk factors necessitate a thorough consideration of other oestrogenic sources. This case report presents a rare case of a coexisting ovarian Brenner tumour and ovarian stromal hyperplasia in a menopausal patient in her 50s with recurrent EH despite earlier regression. The above histology may have provided the additional oestrogenic influence. This patient subsequently underwent a definitive hysterectomy and bilateral salpingo-oophorectomy (BSO). It is important to maintain a high index of suspicion for potential oestrogenic influences in cases of refractory EH that are not identifiable on imaging. BSO should be considered at the time of hysterectomy in such cases of unidentified oestrogenic foci.

Keywords: Gynaecological cancer; Medical education; Menopause (including HRT); Obstetrics, gynaecology and fertility.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Endometrium is slightly prominent for postmenopausal status.
Figure 2
Figure 2
Normal appearance of the right ovary on ultrasound. The left ovary is not seen.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kurman RJ, Carcangiu ML, Herrington CS, et al. . WHO classification of tumours of female Repro ductive organs. 4th ed. [Lyon]: IARC, 2014.
    1. Reed SD, Newton KM, Clinton WL, et al. . Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678.e1–678.e6. 10.1016/j.ajog.2009.02.032 - DOI - PMC - PubMed
    1. Farquhar CM, Lethaby A, Sowter M, et al. . An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999;181:525–9. 10.1016/S0002-9378(99)70487-4 - DOI - PubMed
    1. Scarselli G, Bargelli G, Taddei GL, et al. . Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertil Steril 2011;95:420–2. 10.1016/j.fertnstert.2010.07.1044 - DOI - PubMed
    1. Morelli M, Di Cello A, Venturella R, et al. . Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecol Endocrinol 2013;29:156–9. 10.3109/09513590.2012.730579 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources